The envelope glycoprotein or "spike" from the novel coronavirus (SARS-CoV-2) mediates the virus binding to Angiotensin-converting enzyme 2 (ACE2) for cellular entry and consequently is a prime target for therapeutic development, including antibody-based therapeutics. In this technical note, we investigate the interactions between the spike glycoprotein binding with ACE2. Read on now to learn more!
As marketability goes — and despite a growing unmet medical need — Lyme disease vaccine programs have suffered a futile fate. With its VLA15 candidate, French specialty vaccine company Valneva is trying to change that. Recent positive Phase 2 data bodes well for the effort.
By Michael Mehler, GSK Oncology Cell & Gene Therapy
Cell and gene therapies require operational excellence, complex manufacturing processes, and enormous investment, among other challenges. This article highlights some of these challenges and presents real-world evidence solutions.
By Charles Christy,Lonza Pharma & Biotech
A new business and operating model may address the build or buy dilemma, offering an innovative and agile way to manage demand uncertainty and reduce the risks associated with early investment decisions.
By S. Suryanarayana, B. Daley, D. Schmidt, and J. McCool,Cytovance Biologics
Here we describe a design of experiment (DOE) approach using a definitive screening design (DSD) model to optimize the icIEF development of a glycosylated protein transferrin and an IgG1 monoclonal antibody (mAb).
The vaccine and biotherapeutic manufacturing industries are under pressure to address critical challenges of speed, scale, and supply in their response to SARS-CoV-2. What does this mean for technologies enabling production and how does this impact the future of vaccine and biotherapeutic manufacturing? Find out during our free interactive discussion on December 1, 2020.
This webinar will discuss the use of advanced colonic targeting strategies for oral drug products and other microbiome therapeutics. We will review some of the latest pH, time, and microbial dependent drug delivery technologies that can enable precise targeting of the colon. Options to enhance the solubility of drug products for colonic applications will also be discussed.
Life Science Leader Magazine
Have you heard of Life Science Leader? Check it out today for access to candid interviews with top-tier executives on how they do business.